Effectiveness, safety and feasibility of recombinant hepatitis E vaccine HEV 239 (Hecolin) during an outbreak of hepatitis E in Bentiu, South Sudan

Principal investigator

Robin Nesbitt
Purpose of study
Purpose of study

To estimate the protection conferred by 1 and 2 doses of HEV 239 vaccine against symptomatic hepatitis E. Despite numerous interventions since 2014, hepatitis E cases and deaths continue to be reported in Bentiu, including periods of increased tra...

Study status

  • Concept
  • Protocol & ERB
  • Implementation
  • Completion
  • Archived

Study timeline


No documents uploaded


No publications recorded
Previous study
Next study